## Keli L Hippen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6247795/publications.pdf

Version: 2024-02-01

34 2,382 21 33 g-index

34 34 34 34 4163

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood, 2016, 127, 1044-1051.	1.4	333
2	Massive ex Vivo Expansion of Human Natural Regulatory T Cells (T <sub>regs</sub> ) with Minimal Loss of in Vivo Functional Activity. Science Translational Medicine, 2011, 3, 83ra41.	12.4	326
3	Mitochondrial Integrity Regulated by Lipid Metabolism Is a Cell-Intrinsic Checkpoint for Treg Suppressive Function. Cell Metabolism, 2020, 31, 422-437.e5.	16.2	215
4	Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16814-16819.	7.1	185
5	Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Molecular Therapy, 2016, 24, 570-581.	8.2	168
6	Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions. Cellular and Molecular Immunology, 2017, 14, 521-528.	10.5	147
7	Clinical perspectives for regulatory T cells in transplantation tolerance. Seminars in Immunology, 2011, 23, 462-468.	5.6	95
8	Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood, 2012, 119, 619-628.	1.4	79
9	Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunology Research, 2018, 6, 766-775.	3.4	75
10	The lineage stability and suppressive program of regulatory T cells require protein O-GlcNAcylation. Nature Communications, 2019, 10, 354.	12.8	74
11	miR-146b antagomir–treated human Tregs acquire increased GVHD inhibitory potency. Blood, 2016, 128, 1424-1435.	1.4	70
12	CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration. Science Immunology, 2019, 4, .	11.9	70
13	Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration. Nature Communications, 2016, 7, 12021.	12.8	54
14	Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Frontiers in Immunology, 2018, 9, 57.	4.8	46
15	Induction of immunosuppressive functions and NF-l®B by FLIP in monocytes. Nature Communications, 2018, 9, 5193.	12.8	45
16	Optimization of cGMP purification and expansion of umbilical cord blood–derived T-regulatory cells in support of first-in-human clinical trials. Cytotherapy, 2017, 19, 250-262.	0.7	41
17	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. Blood Advances, 2021, 5, 1425-1436.	<b>5.</b> 2	39
18	miR-142-3p regulates autophagy by targeting ATG16L1 in thymic-derived regulatory T cell (tTreg). Cell Death and Disease, 2018, 9, 290.	6.3	37

#	Article	IF	CITATIONS
19	The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease. Journal of Clinical Investigation, 2018, 128, 4604-4621.	8.2	32
20	Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease. Trends in Immunology, 2020, 41, 77-91.	6.8	31
21	A robust in vitro model for trans-lymphatic endothelial migration. Scientific Reports, 2017, 7, 1633.	3.3	27
22	Regulatory T Cells Condition Lymphatic Endothelia for Enhanced Transendothelial Migration. Cell Reports, 2020, 30, 1052-1062.e5.	6.4	27
23	Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human TÂcells and hematopoietic stem and progenitor cells using base editing. Molecular Therapy, 2022, 30, 130-144.	8.2	23
24	The lymph node stromal laminin $\hat{l}\pm 5$ shapes alloimmunity. Journal of Clinical Investigation, 2020, 130, 2602-2619.	8.2	21
25	Cryopreservation timing is a critical process parameter in a thymic regulatory T-cell therapy manufacturing protocol. Cytotherapy, 2019, 21, 1216-1233.	0.7	18
26	Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease. JCI Insight, 2019, 4, .	5.0	18
27	PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. Nature Communications, 2022, 13, 2176.	12.8	18
28	Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota. Translational Research, 2017, 179, 116-125.	5.0	16
29	ICOSL <sup>+</sup> plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist. Science Translational Medicine, 2020, 12, .	12.4	15
30	Preclinical Testing of Antihuman CD28 Fab′ Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease. Transplantation, 2016, 100, 2630-2639.	1.0	13
31	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. Blood, 2021, 137, 1090-1103.	1.4	8
32	Retinoic acid signaling acts as a rheostat to balance Treg function. , 2022, 19, 820-833.		8
33	Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. Cytotherapy, 2021, 23, 704-714.	0.7	7
34	Treg tissue stability depends on lymphotoxin beta-receptor- and adenosine-receptor-driven lymphatic endothelial cell responses. Cell Reports, 2022, 39, 110727.	6.4	1